SEC Comment Letter for Marijuana Co of America, Inc. (MCOA) (CIK 0001078799) — Oct 6, 2022

Marijuana Co of America, Inc. (MCOA) (CIK 0001078799)
Date: Oct. 6, 2022 · CIK: 0001078799 · Accession: 0000000000-22-011001

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 024-11668

Date

October 6, 2022

Author

cc: Alan T. Hawkins

Form

UPLOAD

Company

Marijuana Co of America, Inc. (MCOA) (CIK 0001078799)

Letter

United States securities and exchange commission logo October 6, 2022 Jesus Quintero Chief Executive Officer Marijuana Co of America, Inc. 633 West Fifth Street, Suite 2826 Los Angeles, CA 90071 Re:Marijuana Co of America, Inc. Offering Statement on Form 1-A Post-qualification Amendment No. 5 Filed September 30, 2022 File No. 024-11668 Dear Jesus Quintero: This is to advise you that we do not intend to review your amendment. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alan T. Hawkins

Show Raw Text

United States securities and exchange commission logo
October 6, 2022
Jesus Quintero
Chief Executive Officer
Marijuana Co of America, Inc.
633 West Fifth Street, Suite 2826
Los Angeles, CA 90071
Re:Marijuana Co of America, Inc.
Offering Statement on Form 1-A
Post-qualification Amendment No. 5
Filed September 30, 2022
File No. 024-11668
Dear Jesus Quintero:
            This is to advise you that we do not intend to review your amendment.
            We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Alan T. Hawkins

SecProbe.io